Fei Zheng

Fei Zheng

Auto-generated profile, based on publicly available information

Fei Zheng

14Harbour BioMed, Shanghai, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2018 in Stem Cells International
Verified
Journal Article
Open access
PDF file
LZLu Zhang
Lu Zhang
FZFei Zheng
Fei Zheng
ZPZhigang Peng
Zhigang Peng
ZHZijing Hu
Zijing Hu
ZYZhi Yang
Zhi Yang
Background. Cancer stem cell (CSC) promotes angiogenesis which plays an important role in tumor occurrence, growth, and metastasis. Accurately, quantifying the tumor vasculature can help understanding CSC characteristics and improve cancer diagnosis, therapy planning, and evaluation. The objective of this study is to present a method for improved angiogenesis assessment. Methods. We proposed a three-dimensional microvessel density (3D MVD) to evaluate tumor angiogenesis and tested it in animal models. Six male Balb/c nude mice were divided into normal group and tumor group. The mice in tumor group were orthotopically implanted human gastric cancer, cell line BGC-823. The phase-contrast images were collected at Shanghai Synchrotron Radiation Facility BL13W beamline, which has much higher soft-tissue contrast and spatial resolution than conventional X-ray. After volume reconstruction and vessel extraction, the 3D models of the angiogenesis were established for MVD calculation. Results. The results showed that the proposed 3D MVD is positively correlated with the pathological changes of the microvessels. It took the advantage of high resolution of the phase-contrast imaging and added three-dimensional information to the existing MVD measure. Conclusions. Our study presents a feasible approach for better understanding of tumor angiogenesis. It may provide doctors and scientists a better tool for cancer investigation and improving medical outcomes.

1 July 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
NZNingning Zhang
Ningning Zhang
TLTian Liu
Tian Liu
MLMing Luo
Ming Luo
JHJihui Hao
Jihui Hao
SQShukui Qin
Shukui Qin
XTXiaolu Tao
Xiaolu Tao
Purpose: The study was conducted to evaluate porustobart (HBM4003), a novel anti–cytotoxic T lymphocyte–associated protein 4 monoclonal antibody, combined with toripalimab as second-line therapy in advanced hepatocellular carcinoma (HCC). Patients and Methods: This phase I study included two cohorts of patients with advanced HCC: cohort 1 included patients who were anti–PD-1/PD-L1 naïve and had received first-line anti-VEGFR tyrosine kinase inhibitor, and cohort 2 included patients who had failed prior first-line anti–PD-1/PD-L1 and anti-VEGF/VEGFR therapies. Porustobart (0.45 mg/kg) and toripalimab (240 mg) were administered every 21 days. The primary endpoint was the objective response rate (ORR). Results: In total, 16 patients were enrolled in cohort 1 and 12 in cohort 2. In the 26 patients with evaluable efficacy data, the ORR was 23.1% (95% confidence interval, 9.0–43.6). Cohort 1 exhibited an ORR of 40.0%, whereas cohort 2 presented no objective response. The median progression-free survival was 4.2 months, with 5.7 months for cohort 1 and 3.8 months for cohort 2. Biomarker exploration revealed higher abundance of intratumoral regulatory T cells in responders before treatment and a substantial elevation of CD4+Ki67+ and CD8+Ki67+ T cells after treatment. For safety, treatment-emergent adverse events were reported in 27 patients (96.4%), and treatment-related adverse events were reported in 25 patients (89.3%), among whom 13 (46.5%) had grade ≥3 treatment-related adverse events. Serious adverse events were observed in 12 patients (42.9%), and treatment-related serious adverse events were observed in nine patients (32.1%). Conclusions: The combination of porustobart and toripalimab shows promising efficacy as a second-line therapy in anti–PD-1/PD-L1–naïve patients with advanced HCC and a manageable safety profile.

1 August 2025
Verified
Other
Open access
NZNingning Zhang
Ningning Zhang
TLTian Liu
Tian Liu
MLMing Luo
Ming Luo
JHJihui Hao
Jihui Hao
SQShukui Qin
Shukui Qin
XTXiaolu Tao
Xiaolu Tao
Supplementary Methods S1. Supplementary details of study design, patient enrollment, statistical analysis and sample size calculation.

1 August 2025
Verified
Other
Open access
NZNingning Zhang
Ningning Zhang
TLTian Liu
Tian Liu
MLMing Luo
Ming Luo
JHJihui Hao
Jihui Hao
SQShukui Qin
Shukui Qin
XTXiaolu Tao
Xiaolu Tao
Supplementary Figure S2. Changes in peripheral blood cytokines before and after treatment.